2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Pediatric, Young Adult
PAPER

4884 Immune interaction regulates quiescent/slow-cycling MPP4 through MHCII-dependent mechanisms

Ashok Arasu, PhD, Sumit Kumar, PhD2, E. Broderick Hinton3, H. Leighton Grimes, PhD4, David Hildeman, PhD5, Rob S Welner, PhD6, Daniel Lucas-Alcaraz, PhD7, Damien Reynaud, PhD8
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Children's Hospital Medical Center, Cincinnati, Cincinnati, Ohio, United States, University of Cincinnati, College of Medicine, Cincinnati, Ohio, United States
5 Children's Hospital Medical Center, Cincinnati, Cincinnati, Ohio, United States, University of Cincinnati, College of Medicine, Cincinnati, Ohio, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, College of Medicine, Cincinnati, Ohio, United States
8 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati, College of Medicine, Cincinnati, Ohio, United States

The bone marrow (BM) is the site of blood cell production and constitutes a complex immune environment in which hematopoietic stem and progenitor cells (HSPCs) are exposed to inflammatory mediators, and immune cell populations. Increasing evidence indicates that immune interactions play important roles in regulating HSPC activity. Notably, expression of the major histocompatibility complex class II (MHCII) has been shown to mark highly quiescent hematopoietic stem cell (HSC) subsets (Li et al, blood 2022; Hernández-Malmierca et al, Cell Stem Cell 2022). Whether similar mechanisms extend to downstream multipotent progenitors remains poorly understood.

In a recent work, we identified a previously unrecognized quiescent/slow-cycling population within the Flt3+ multipotent progenitor compartment (MPP4) characterized by reduced cell-cycle activity, prolonged label retention, and extended hematopoietic reconstitution capacity following non-myeloablative transplantation (Solomon et al., JEM 2024). Through transcriptional profiling and flow cytometric analyses, we identified MHCII as a marker associated with quiescent/slow-cycling MPP4 cells. CITE-seq revealed that, at steady state, MHCII+ MPP4 cells display a distinct inflammatory transcriptional program enriched in interferon-responsive genes. Consistent with this profile, MHCII expression was selectively upregulated in MPP4 cells following LPS-induced inflammatory stress. To define the pathways regulating MHCII expression, we analyzed a panel of cytokine-signaling mutant mice and found that MHCII induction requires interferon-γ receptor (Ifngr1) and Stat1 signaling, whereas type I interferon signaling through Ifnar1 is dispensable. Functional studies demonstrated that MHCII is required for maintenance of this progenitor subset as MHCII deficiency resulted in a selective reduction of the MPP4 compartment at steady state and impaired the reconstitution capacity of quiescent/slow-cycling MPP4 in non-myeloablative transplantation. Mechanistically, MHCII+ MPP4 cells expressed the co-stimulatory molecule ICOSL, suggesting potential interactions with adaptive immune cells. Consistent with this model, lymphopenic Rag1–/– mice exhibited reductions in MPP4 numbers comparable to those observed in MHCII-deficient animals. Although in situ imaging did not identify a discrete immune niche, it supported the possibility of direct interactions between quiescent/slow-cycling MPP4 and BM T cells.

Together, these findings identify MHCII as both a defining marker and a functional regulator of the quiescent/slow-cycling MPP4 cells, suggesting that their maintenance and function are supported by interactions with adaptive immune cells. These observations parallel previous findings in quiescent HSCs and support the existence of an MHCII-associated developmental pathway extending from HSCs to downstream multipotent progenitors. More broadly, our study reveals a previously unrecognized immune-progenitor crosstalk that may contribute to the regulation of early hematopoietic differentiation, progenitor maintenance, and regenerative capacity.
Ashok Arasu, PhD: No relevant conflicts of interest to declare.